

業績集

1. Fukuhara H, Sato YT, Hou J, Iwai M, Todo T. Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12. *Commun Med (Lond)*. 3, 40, 2023.
2. Fukuhara H, Takeshima Y, Todo T. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumor. *Cancer Sci*, 112, 3293-3301, 2021.
3. Taguchi S, Tambo M, Watanabe M, Machida H, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Yokoyama K, Fukuhara H. Prospective validation of Vesical Imaging-Reporting and Data System (VI-RADS) using a next-generation magnetic resonance imaging scanner: Is denoising deep learning reconstruction useful? *J Urol* 205. 686-692, 2021.
4. Higashihara E, Fukuhara H, Ouyang J, Lee J, Nutahara K, Tanbo M, Yamaguchi T, Taguchi S, Muto S, Kanayama S, Miyazaki I, Horie S. Estimation of changes in kidney volume growth rate in autosomal dominant polycystic kidney disease. *Kidney Int Rep.*, 5, 1459-1471, 2020.
5. Masuda K, Aizawa N, Watanabe D, Okegawa T, Kume H, Igawa Y, Fukuhara H. Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats. *Scientific Reports*. 10, 4182, 2020.
6. Iwaki T, Akiyama Y, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis. *Eur Urol Open Sci*. 49, 44-50, 2023.
7. Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. *Urology*. 2023, in press.

8. Ochiai K, Mochida Y, Nagase T, Fukuvara H, Ymaguchi Y, Nagase M. Upregulation of piezo2 in the mesangial, renin, and perivascular mesenchymal cells of the kidney of Dahl salt-sensitive hypertensive rats and its reversal by esaxerenone. *Hypertens Res.* 2023; in press.
9. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuvara H. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? *Int Urogynecol J.* 34, 853-859, 2023.
10. Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuvara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. *BMC Urol.* 22, 177, 2022.
11. Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuvara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). *Int J Urol.* 29, 1462-1469, 2022.
12. Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuvara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M. Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study. *Int J Urol.* 29, 1271-1278, 2022.
13. Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue

M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M. Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. *Jpn J Clin Oncol.* 52, 1056-1061, 2022.

14. Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Fukuhara H, Yokoyama K. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. *Eur Radiol.* 32, 7513-7521, 2022.
15. Shishido T, Okegawa T, Hayashi K, Masuda K, Taguchi S, Nakamura Y, Tambo M, Fukuhara H. Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: A comparison of clinical and perioperative outcomes. *Asian J Urol.* 9, 119-124, 2022.
16. Mochida Y, Ochiai K, Nagase T, Nonomura K, Akimoto Y, Fukuhara H, Sakai T, Matsumura G, Yamaguchi Y, Nagase M. Piezo2 expression and its alteration by mechanical forces in mouse mesangial cells and renin-producing cells. *Sci Rep.* 12, 4197, 2022.
17. Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. *J Immunother Cancer.* 10, e003965, 2022.
18. Nakamura Y, Taguchi S, Kinjo M, Tanbo M, Okegawa T, Fukuhara H. Adrenal metastasis in nivolumab-treated renal cell carcinoma: A unique entity as a sanctuary site. *Int. J Urol.* 29, 597-599, 2022.

19. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. *Int J Clin Oncol.* 27, 418-426, 2022.
20. Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. *Int J Clin Oncol.* 27, 194-201, 2022.
21. Kinjo M, Tanba M, Masuda K, Nakamura Y, Tanbo M, Fukuhara H. Comparison of effectiveness between modified transvaginal mesh surgery and vaginal pessary treatment in patients with symptomatic pelvic organ prolapse. *Low Urin Tract Symptoms.* 14, 64-71, 2022.
22. Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. *Jpn J Clin Oncol.* 52, 65-72, 2022.
23. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer; results from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. *Urol Oncol.* 40, 56.e9-e15, 2022.
24. Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K,

Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. *Prostate Cancer Prostatic Dis.* 25, 666-671, 2022.

25. Taguchi S, Watanabe M, Tambo M, Machida H, Yokoyama K, Fukuhara H. Proposal for a new Vesical Imaging-Reporting and Data System (VI-RADS)-based algorithm for the management of bladder cancer: A paradigm shift from the current transurethral resection of bladder tumor (TURBT)-dependent practice. *Clinical Genitourinary Cancer* 20, e291-e295, 2022.
26. Kitahama K, Yoshiike S, Nagahama K, Ninomiya N, Okegawa T, Fukuhara H, Nabeshima K, Oka T, Shibahara J. Well-differentiated papillary mesothelial tumor presenting as an encysted hydrocele of the spermatic cord. *Pathol Int.* 72, 352-354, 2022.
27. Higashihara E, Nutahara K, Itoh M, Okegawa T, Tambo M, Yamaguchi T, Nakamura Y, Taguchi S, Kaname S, Yokoyama K, Yoshioka T, Fukuhara H. Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD. *Kidney Int Rep.* 7, 270-281, 2021.
28. Kitamura J, Taguchi S, Okegawa T, Honda K, Kii T, Tomida Y, Matsumoto R, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Isomura A, Hayashi A, Kamma H, Higashihara E, Shibahara J, Fukuhara H. Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report. *BMC Med Genomics.* 14, 217, 2021
29. Taguchi S, Kawai T, Nakagawa T, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Takahashi S, Kume H. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study. *Sci Rep.* 11, 15623, 2021.

30. Shigemori K, Higashihara E, Itoh M, Yoshida H, Yamamoto K, Nutahara K, Shiokawa Y, Kaname S, Tambo M, Yamaguchi T, Taguchi S, Yoshioka T, Yokoyama K, Fukuhara H. PKD1- associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease. *J Stroke Cerebrovasc Dis.* 30, 105943, 2021.
31. Kii T, Taguchi S, Nagahama K, Shimoyamada H, Honda K, Tomida Y, Matsumoto R, Kitamura J, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Higashihara E, Shibahara J, Fukuhara H. Pigmented median raphe cyst of the penis that developed after middle age without infection or trauma history. *IJU Case Reports*, 4, 172-175, 2021.
32. Taguchi S, Morikawa T, Shibahara J, Fukuhara H. Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review. *Int J Urol.* 28, 614-621, 2021.
33. Taguchi S, Nakagawa T, Uemura Y, Akamatsu N, Gono W, Naito A, Kawai T, Kume H, Fukuhara H. Comparison of Major Definitions of Sarcopenia Based on the Skeletal Muscle Index in Patients with Urothelial Carcinoma. *Future Oncology*, 17, 197-203, 2021.
34. Kinjo M, Nakamura Y, Taguchi S, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. *Urology*, 151, 24-30, 2021.
35. Uchihashi T, Nakahara H, Fukuhara H, Iwai M, Ito H, Sugauchi A, Tanaka M, Kogo M, Todo T. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis, *Mol Ther Oncolytics*. 22, 388-398, 2021.

36. Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. *Prostate Cancer Prostatic Dis.* 2021, in press.
37. Matsumura S, Nakamori M, Tsuji T, Kato T, Nakamura M, Ojima T, Fukuhara H, Ino Y, Todo T, Yamaue H. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. *Oncotarget*, 12, 344-354, 2021.
38. Inoue T, Okada S, Hamamoto S, Miura H, Matsuzaki J, Tambo M, Fukuhara H, Fujisawa M, Matsuda T, Nutahara K. Evaluation of flexible ureteroscope with an omni-directional bending tip, using a JOYSTICK unit (URF-Y0016); an ex-vivo study. *World Journal of Urology*, 39, 209-215, 2021.
39. Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S. Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. *Clin Cancer Res.* 27, 6164-6173, 2021.
40. Higashihara E, Horie S, Muto S, Kawano H, Tanbo M, Yamaguchi T, Taguchi S, Kaname S, Yokoyama K, Yoshioka T, Fukukawa T, Fukuhara H. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. *American Journal of Nephrology*, 51, 891-890, 2020.

41. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Okegawa T, Fukuhara H. Effects on depression and anxiety after mid-urethral sling surgery for female stress urinary incontinence. *Research and Reports in Urology*, 12, 495-501, 2020.
42. Omura S, Taguchi S, Miyagawa S, Matsumoto R, Samejima M, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Higashihara E, Fukuhara H. Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma. *BMC Urology*, 20, 133, 2020.
43. Naito A, Taguchi S, Suzuki M, Kawai T, Uchida K, Fujimura T, Fukuhara H, Kume H. Transient acute kidney injury observed immediately after robot-assisted radical prostatectomy but not after open radical prostatectomy. *Molecular and Clinical Oncology*, 13, 18, 2020.
44. Taguchi S, Shiraishi K, Fukuhara H. Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer. *Jpn J Clin Oncol.* 50, 963-969, 2020.
45. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, Suzuki M, Kume H, Fukuhara H. Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. *BMC Cancer*, 20, 371, 2020.
46. Okegawa T, Omura S, Samejima M, Ninomiya N, Taguchi S, Nakamura Y, Yamaguchi T, Tambo M, Fukuhara H. Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy: comparison of oncological outcomes at a single center. *Prostate Int.* 8, 16-21, 2020.
47. Tambo M, Taguchi S, Nakamura Y, Okegawa T, Fukuhara H. Presepsin and

procalcitonin as predictors of sepsis based on the new Sepsis-3 definition in obstructive pyelonephritis. *BMC Urol.* 20, 23, 2020.

48. Kakutani S, Asamoto M, Araki F, Chen YN, Shinokawa M, Okagami Y, Ohata T, Taguchi S, Yamada Y, Takeshima Y, Kume H, Yamada Y, Aihara M, Ito N, Fukuhara H. Prospective evaluation of visual function in patients with ocular diseases after robotic-assisted laparoscopic prostatectomy. *Int J Urol.* 27, 307-313, 2020.
49. Tambo M, Inoue T, Miura H, Matsuzaki J, Nutahara K, Hamamoto S, Okada S, Fukuhara H, Fujisawa M, Matsuda T. A novel flexible ureteroscope with omnidirectional bending tip using joystick-type control unit (URF-Y0016): initial validation study in bench models. *J Endourol.* 34, 676-681, 2020.
50. Shimizu T, Yamaguchi K, Yamamoto M, Kurioka R, Kino Y, Matsunaga W, Nakao S, Fukuhara H, Tanaka A, Gotoh A, Mabuchi M. Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug. *Bioorganic & Medicinal Chemistry Letter* 30, 126744, 2020.
51. Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibahara J, Fukuhara H, Komiyama M, Watanabe SI, Tamura K, Kawai A, Shibata T, Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. *Histopathology* 76, 509-520, 2020.
52. Taguchi S, Nakagawa T, Fukuhara H. Inconsistencies in currently used definitions of sarcopenia in oncology. *Annals of Oncology* 31, 318-319, 2020.
53. Nakato R, Wada Y, Nakaki R, Nagae G, Katou Y, Tsutsumi S, Nakajima N, Fukuhara H, Iguchi A, Kohro T, Kanki Y, Saito Y, Kobayashi M, Izumi-Taguchi A, Osato N, Tatsuno K, Kamio A, Hayashi-Takanaka Y, Wada H, Ohta S, Aikawa M, Nakajima H, Nakamura M, McGee RC, Heppner KW, Kawakatsu T, Genno M, Yanase H, Kume H,

Senbonmatsu T, Homma Y, Nishimura S, Mitsuyama T, Aburatani H, Kimura H, Shirahige K. Comprehensive epigenome characterization reveals diverse transcriptional regulation across human vascular endothelial cells. *Epigenetics Chromatin.* 12, 77, 2019.

54. Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Nakagawa K, Abe O, Kume H, Fukuhara H*. Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. *Radiother Oncol.* 140, 62-66, 2019.

55. Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. *Nat Commun.* 10, 1894, 2019.

56. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. *Neurourol Urodyn* 38, 1067-1075, 2019.

57. Akiyama Y, Daichi M, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. *J Urol.* 202, 290-300, 2019.

58. Kinjo M, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. *Urol Int.* 102, 331-335, 2019.
59. Taguchi S, Fukuhara H*, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. *Jpn J Clin Oncol.* 49, 201-209, 2019.
60. Samejima M, Taguchi S, Miyagawa S, Matsumoto R, Omura S, Ninomiya N, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Koba T, Matsuki R, Jimbo I, Motoyasu A, Tsumura T, Shimoyamada H, Shibahara J, Sakamoto Y, Fukuhara H. Acute hypotension induced by suction of cystic fluid containing extremely high concentrations of catecholamines during resection of giant pheochromocytoma. *IJU Case Rep.* 2, 218-220, 2019.
61. Taguchi S, Nakagawa T, Fukuhara H. Re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. *Eur Urol* 2019. *Eur Urol*, S0302-2838, 30345-30348, 2019.
62. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. *Kidney Int.* 96: 159-169. 2019
63. Higashihara E, Yamamoto K, Kaname S, Okegawa T, Tanbo M, Yamaguchi T, Shigemori K, Miyazaki I, Yokoyama K, Nutahara K : Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases. *Clin Exp Nephrol.* 23, 100-111, 2019.

64. Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M. Validation of the Grade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. *Sci Rep.* 9, 13218, 2019.
65. Fujisaki A, Kinjo M, Shimoinaba M, Honda S, Yoshimura Y. An evaluation of the impact of post-hysterectomy vesicovaginal fistula repair on the mental health of patients in a developed country. *Int Urogynecol J.* 2019, in press.
66. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwierc FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. *Kidney Int.* 96, 159-169, 2019.
67. Gonda K, Akama T, Nakamura T, Hashimoto E, Kyoya N, Rokkaku Y, Maejima Y, Horita S, Tachibana K, Abe N, Ohtake T, Shimomura K, Kono K, Saji S, Takenoshita S, Higashihara E. Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report. *J Med Case Rep.* 13, 381, 2019.
68. Fujimura T, Fukuhara H, Yamada Y, Taguchi S, Sugihara T, Niimi A, Nakamura M, Nakagawa T, Igawa Y, Homma Y, Kume H. Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. *Anticancer Res.* 38: 6529-6535, 2018.
69. Kinoshita Y, Sugihara T, Yasunaga H, Matsui H, Ishikawa A, Fujimura T, Fukuhara H, Ishibashi Y, Fushimi K, Homma Y. Hospital-volume effects on perioperative

outcomes in peritoneal dialysis catheter implantation: analysis of 2,505 cases. *Perit Dial Int.* 38, 419-423, 2018.

70. Taguchi S, Fukuhara H*, Miyakawa J, Morikawa T, Naito A, Kawai T, Fujimura T, Kume H. Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. *Jpn J Clin Oncol.* 48, 692-694, 2018.
71. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. *Mol Clin Oncol.* 8, 665-670, 2018.
72. Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. *Jpn J Clin Oncol.* 48, 485-49, 2018.
73. Aizawa N, Watanabe D, Fukuhara H, Fujimura T, Kume H, Homma Y, Igawa Y. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relaxation with bladder myogenic contractions in male rats with bladder outlet obstruction. *Neurourol Urodyn.* 37, 1897-1903, 2018.
74. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y and Homma Y. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in patients with Hunner-type interstitial cystitis. *Neurourol Urodyn.* 37, 1441-1447, 2018.
75. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H and Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. *Neurourol Urodyn.* 37, 1113-1119, 2018.

76. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, Igawa Y, Homma Y. Predictors of Early Continence after Robot-assisted Radical Prostatectomy. *Low Urin Tract Symptoms*. 10, 287-291, 2018.
77. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okanoya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. *World J Urol*. 36, 249-256, 2018.
78. Arakawa K, Hata K, Yamamoto Y, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Yoshida M, Fukuhara H, Fujishiro M, Morikawa T, Yamasoba T, Koike K, Fukayama M, Watanabe T. Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. *BMC Cancer* 18, 24, 2018.
79. Sato M, Taguchi A, Fukui Y, Kawata A, Taguchi S, Kashiyama T, Eguchi S, Inoue T, Tomio K, Tanikawa M, Sone K, Mori M, Nagasaka K, Adachi K, Ikemura M, Domoto Y, Arimoto T, Oda K, Fukayama M, Osuga Y, Fujii T. Blood Vessel Invasion Is a Strong Predictor of Postoperative Recurrence in Endometrial Cancer. *Int J Gynecol Cancer* 28, 875-881, 2018.
80. Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K. A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. *Clin Exp Nephrol*. 22(2):395-404, 2018.
81. Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and

enzalutamide treatment in castration-resistant prostate cancer patients. Prostate. 78(8):576-582, 2018

82. Fujita N, Tambo M, Terado Y, Fujita M, Okegawa T, Nutahara K. Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum. Case Rep Oncol. 4;11(1):6-10, 2018.

83. Kinjo M, Yoshimura Y, Kitagawa Y, Okegawa T, Nutahara K. Sexual activity and quality of life in Japanese pelvic organ prolapse patients after transvaginal mesh surgery. J Obstet Gynaecol Res. 44(7):1302-1307, 2018

84. Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. Clin Exp Nephrol. 22(5):1213-1223, 2018.

85. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. Low Urin Tract Symptoms. 10, 148-151, 2018.